Yamo Deniz
Regeneron (United States)(US)Progenics Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Asthma and respiratory diseases, IL-33, ST2, and ILC Pathways, Eosinophilic Esophagitis, Allergic Rhinitis and Sensitization, Sinusitis and nasal conditions
Most-Cited Works
- → The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation(2005)460 cited
- → Uncontrolled asthma: A review of the prevalence, disease burden and options for treatment(2006)318 cited
- → Aspirin sensitivity and severity of asthma: Evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma(2005)220 cited
- → Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis(2022)216 cited
- → Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma(2003)188 cited
- → Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma(2003)183 cited
- → Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma(2005)167 cited
- → Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation(2021)149 cited
- → Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis(2021)135 cited
- → Severity assessment in asthma: An evolving concept(2005)94 cited